Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer

Table 2 Demographics and tumor parameters of eligible patients

Characteristic	GEM + IRE group (n = 33)	GEM group (n = 35)	P value
Age, yr
Median	63	65
Range	45-86	39-81
Sex
Female	18 (54.5)	19 (54.3)	0.983
Male	15 (45.5)	16 (45.7)
Pathology
Adenocarcinoma	26	23
Lesion size (cm)	4.1 (3.0-5.0)	3.9 (3.0-5.0)
Tumor location
Head and neck	23 (23.3)	21 (26.7)	0.686
Body and tail	5 (40.0)	6 (50.0)
Previous surgical therapy			0.479
Gastrojejunostomy	3 (9.1)	4 (11.4)
Hepaticojejunostomy	1 (3.0)	2 (5.7)
Double bypass	2 (6.1)	0 (0.0)
Plastic retrievable endoprosthesis	1 (3.0)	1 (2.9)
Performance status			0.757
0	12 (36.3)	14 (40.0)
1	21 (63.7)	21 (60.0)
Accepted treatment			0.681
Biliary bypass and gastrojejunostomy	2 (6.1)	1 (2.9)
Cholecystectomy	1 (3.0)	0 (0.0)
Gastroenterostomy	2 (6.1)	2 (5.7)
Herb therapy	2 (6.1)	3 (8.6)
Immunotherapy	1 (3.0)	0 (0.0)

IRE: Irreversible electroporation; GEM: Gemcitabine.